84 related articles for article (PubMed ID: 8279841)
1. [Strategy for the ovarian cancer treatment].
Ochiai K
Gan To Kagaku Ryoho; 1993 Dec; 20(16):2454-60. PubMed ID: 8279841
[TBL] [Abstract][Full Text] [Related]
2. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
3. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group).
McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-Pearson DL; Davidson M
Semin Oncol; 1996 Oct; 23(5 Suppl 12):40-7. PubMed ID: 8941409
[TBL] [Abstract][Full Text] [Related]
4. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
Harper P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
[TBL] [Abstract][Full Text] [Related]
5. Gynecological malignancies.
Schaebler DL; Schilder RJ; Young RC
Cancer Chemother Biol Response Modif; 1996; 16():564-91. PubMed ID: 8639401
[TBL] [Abstract][Full Text] [Related]
6. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest.
Gadducci A; Carnino F; Chiara S; Brunetti I; Tanganelli L; Romanini A; Bruzzone M; Conte PF
Gynecol Oncol; 2000 Feb; 76(2):157-62. PubMed ID: 10637064
[TBL] [Abstract][Full Text] [Related]
7. [The treatment of borderline ovarian tumors and its prognosis].
Li ZX; Qiu XF
Zhonghua Fu Chan Ke Za Zhi; 1994 Apr; 29(4):207-9, 251-2. PubMed ID: 8082441
[TBL] [Abstract][Full Text] [Related]
8. [Cytoreductive surgery plus combined chemotherapy for the treatment of advanced ovarian cancer].
Li M; Huang X
Zhonghua Fu Chan Ke Za Zhi; 1996 Oct; 31(10):621-3. PubMed ID: 9275460
[TBL] [Abstract][Full Text] [Related]
9. [Therapeutic and prognostic results of a prospective multicenter ovarian cancer study of FIGO stages I and II].
Sevelda P; Gitsch E; Dittrich C; Haider F; Czerwenka K; Schemper M; Salzer H
Geburtshilfe Frauenheilkd; 1987 Mar; 47(3):179-85. PubMed ID: 3556307
[TBL] [Abstract][Full Text] [Related]
10. Optimal debulking surgery is an independent prognostic factor in patients with FIGO IIIC primary epithelial ovarian carcinoma.
Wang PH; Yuan CC; Shyong WY; Chiang SC; Chao JY; Yen MS; Ng HT
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Mar; 63(3):220-5. PubMed ID: 10746418
[TBL] [Abstract][Full Text] [Related]
11. [Survival in ovarian cancer treated in a gynecological department of a central hospital].
Dragsted NO; Nørgaard M; Bøsling KB
Ugeskr Laeger; 1997 May; 159(20):3003-9. PubMed ID: 9190729
[TBL] [Abstract][Full Text] [Related]
12. [Multimodal treatment for advanced, ovarian cancer patients with poor performance status--its effectiveness and limitations].
Shimizu Y; Tatsuki Y; Fujimoto I; Yamauchi K; Hasumi K; Masubuchi K
Nihon Sanka Fujinka Gakkai Zasshi; 1992 Dec; 44(12):1551-8. PubMed ID: 1484219
[TBL] [Abstract][Full Text] [Related]
13. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
Wadler S; Yeap B; Vogl S; Carbone P
Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
[TBL] [Abstract][Full Text] [Related]
14. Analysis of treatment failures and survival of patients with fallopian tube carcinoma: a cooperation task force (CTF) study.
Gadducci A; Landoni F; Sartori E; Maggino T; Zola P; Gabriele A; Rossi R; Cosio S; Fanucchi A; Tisi G
Gynecol Oncol; 2001 May; 81(2):150-9. PubMed ID: 11330942
[TBL] [Abstract][Full Text] [Related]
15. Maximal cytoreductive surgery and high dose cisplatin chemotherapy for advanced ovarian cancer.
Ochiai K; Takakura S; Isonishi S; Sasaki H; Terashima Y
Asia Oceania J Obstet Gynaecol; 1993 Dec; 19(4):375-81. PubMed ID: 8135669
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study.
Susumu N; Sagae S; Udagawa Y; Niwa K; Kuramoto H; Satoh S; Kudo R;
Gynecol Oncol; 2008 Jan; 108(1):226-33. PubMed ID: 17996926
[TBL] [Abstract][Full Text] [Related]
17. Consolidation radiotherapy after carboplatin-based chemotherapy in radically operated advanced ovarian cancer.
Pickel H; Lahousen M; Petru E; Stettner H; Hackl A; Kapp K; Winter R
Gynecol Oncol; 1999 Feb; 72(2):215-9. PubMed ID: 10021304
[TBL] [Abstract][Full Text] [Related]
18. Preliminary analysis of RTOG 9708: Adjuvant postoperative radiotherapy combined with cisplatin/paclitaxel chemotherapy after surgery for patients with high-risk endometrial cancer.
Greven K; Winter K; Underhill K; Fontenesci J; Cooper J; Burke T;
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):168-73. PubMed ID: 15093913
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy with paclitaxel, ifosfamide, and cisplatin for the treatment of squamous cell cervical cancer: the experience of Monza.
Zanetta G; Fei F; Mangioni C
Semin Oncol; 2000 Feb; 27(1 Suppl 1):23-7. PubMed ID: 10697040
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II study of paclitaxel, cisplatin, and cyclophosphamide in advanced ovarian carcinoma: preliminary results.
Coeffic D; Benhammouda A; Antoine EC; Rixe O; Paraiso D; Auclerc G; Nizri D; Renody N; Grapin JP; Mularoni E; Rattini E; Soubrane C; Weil M; Mortier N; Khayat D
Semin Oncol; 1996 Dec; 23(6 Suppl 15):5-8. PubMed ID: 8996589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
